Unveiling a Hidden Biomarker of Inflammation and Tumor Progression: The 65 kDa Isoform of MMP-9 New Horizons for Therapy
Rocco Rossano(University of Basilicata), Paolo Riccio(University of Basilicata), Margherita Macellaro(University of Basilicata), Marilena Larocca(University of Basilicata), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo)
Cited by 6
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes
|Journal of Neuroimmunology|2003|177
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Lapatinib in breast cancer
|Annals of Oncology|2007|129